Trial Profile
CD19-specific T cell Infusion in Patients with B-Lineage Lymphoid Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2022
Price :
$35
*
At a glance
- Drugs Anti-CD19 CAR-transduced T cells (Primary)
- Indications Acute biphenotypic leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 08 Mar 2021 Status changed from active, no longer recruiting to completed.
- 17 May 2019 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 09 Jan 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2020.